Pieter-Jan Carpentier1, Frances R Levin. 1. From the Reinier van Arkel Psychiatric Institute, 's-Hertogenbosch, the Netherlands (Dr. Carpentier); Department of Psychiatry, College of Physicians and Surgeons, Columbia University (Dr. Levin); Division of Substance Abuse, New York State Psychiatric Institute, New York, NY (Dr. Levin).
Abstract
LEARNING OBJECTIVES: After participating in this activity, learners should be better able to:• Evaluate pharmacologic treatment of attention deficit/hyperactivity disorder (ADHD) in patients with substance use disorder (SUD) • Assess the causes of the diminished efficacy of ADHD medication in patients with comorbid SUD OBJECTIVE: Substance use disorder (SUD) and attention-deficit/hyperactivity disorder (ADHD) frequently co-occur, and the presence of ADHD complicates the treatment of the addiction. Pharmacotherapy is a potent intervention in childhood and adult ADHD, but findings have been mixed in adolescent and adult ADHD patients with SUDs. This review focuses on several contributing factors and possible explanations, with implications both for future research and for clinical practice. METHOD: This systematic review examined all randomized, placebo-controlled trials of pharmacotherapy for ADHD in adult and adolescent SUD patients. RESULTS: The number of studies is limited, and several studies are hampered by qualitative flaws. The results, in general, are inconclusive for most medications studied, but more recent trials using psychostimulants in robust dosing have demonstrated significantly positive results. CONCLUSION: In reviewing these trials, possible explanations relating to the particular characteristics and problems of this complex patient group are discussed. Several factors, including ADHD symptom severity, psychiatric comorbidity, persistent drug use, choice of medication, and concomitant psychosocial intervention, influence study results. Taking these factors into account may improve the likelihood of detecting significant effects in future research, as the recent positive trials have indicated, and may help in the appropriate selection of pharmacotherapy in clinical practice.
LEARNING OBJECTIVES: After participating in this activity, learners should be better able to:• Evaluate pharmacologic treatment of attention deficit/hyperactivity disorder (ADHD) in patients with substance use disorder (SUD) • Assess the causes of the diminished efficacy of ADHD medication in patients with comorbid SUD OBJECTIVE: Substance use disorder (SUD) and attention-deficit/hyperactivity disorder (ADHD) frequently co-occur, and the presence of ADHD complicates the treatment of the addiction. Pharmacotherapy is a potent intervention in childhood and adult ADHD, but findings have been mixed in adolescent and adult ADHDpatients with SUDs. This review focuses on several contributing factors and possible explanations, with implications both for future research and for clinical practice. METHOD: This systematic review examined all randomized, placebo-controlled trials of pharmacotherapy for ADHD in adult and adolescent SUD patients. RESULTS: The number of studies is limited, and several studies are hampered by qualitative flaws. The results, in general, are inconclusive for most medications studied, but more recent trials using psychostimulants in robust dosing have demonstrated significantly positive results. CONCLUSION: In reviewing these trials, possible explanations relating to the particular characteristics and problems of this complex patient group are discussed. Several factors, including ADHD symptom severity, psychiatric comorbidity, persistent drug use, choice of medication, and concomitant psychosocial intervention, influence study results. Taking these factors into account may improve the likelihood of detecting significant effects in future research, as the recent positive trials have indicated, and may help in the appropriate selection of pharmacotherapy in clinical practice.
Authors: Frances R Levin; Suzette M Evans; Daniel J Brooks; Aparna S Kalbag; Fatima Garawi; Edward V Nunes Journal: Drug Alcohol Depend Date: 2005-08-15 Impact factor: 4.492
Authors: Timothy E Wilens; Lenard A Adler; Margaret D Weiss; David Michelson; Janet L Ramsey; Rodney J Moore; Didier Renard; Kathleen T Brady; Paula T Trzepacz; Leslie M Schuh; Lisa M Ahrbecker; Louise R Levine Journal: Drug Alcohol Depend Date: 2008-04-09 Impact factor: 4.492
Authors: Paula D Riggs; Shannon K Hall; Susan K Mikulich-Gilbertson; Michelle Lohman; Ashley Kayser Journal: J Am Acad Child Adolesc Psychiatry Date: 2004-04 Impact factor: 8.829
Authors: Geurt Van de Glind; Christoffer Brynte; Arvid Skutle; Sharlene Kaye; Maija Konstenius; Frances Levin; Frieda Mathys; Zsolt Demetrovics; Franz Moggi; Josep Antoni Ramos-Quiroga; Arnt Schellekens; Cleo Crunelle; Geert Dom; Wim van den Brink; Johan Franck Journal: Eur Addict Res Date: 2020-06-29 Impact factor: 3.015
Authors: Zheng Chang; Laura Ghirardi; Patrick D Quinn; Philip Asherson; Brian M D'Onofrio; Henrik Larsson Journal: Biol Psychiatry Date: 2019-04-17 Impact factor: 13.382
Authors: Marion Selfridge; Kiffer Card; Taylor Kandler; Erin Flanagan; Emily Lerhe; Ash Heaslip; Anne Nguyen; Matthew Moher; Bernie Pauly; Karen Urbanoski; Chris Fraser Journal: Int J Drug Policy Date: 2022-05-04
Authors: Corrado Manni; Giada Cipollone; Alessandro Pallucchini; Angelo G I Maremmani; Giulio Perugi; Icro Maremmani Journal: Int J Environ Res Public Health Date: 2019-10-15 Impact factor: 3.390
Authors: Alessandro Pallucchini; Marco Carli; Angelo G I Maremmani; Marco Scarselli; Giulio Perugi; Icro Maremmani Journal: J Clin Med Date: 2021-05-05 Impact factor: 4.241
Authors: María Vallejo-Valdivielso; Pilar de Castro-Manglano; Azucena Díez-Suárez; Juan J Marín-Méndez; Cesar A Soutullo Journal: Clin Pract Epidemiol Ment Health Date: 2019-12-31